Acrivon Therapeutics, Inc. (ACRV)

8.14 -0.09 (-1.09%) At close: 04:00PM EDT

Acrivon Therapeutics, Inc.

480 Arsenal Way
Suite 100
Watertown, MA 02472
United States
617 207 8979
https://www.acrivon.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 58

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Peter Blume-Jensen M.D., Ph.D.	Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer	977.7k	N/A	1963
Ms. Kristina Masson M.B.A., Ph.D.	Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director	739.78k	N/A	1981
Ms. Mary-Alice Miller J.D.	Chief Legal Officer	587.11k	N/A	1974
Mr. Rasmus Holm-Jorgensen	Chief Financial Officer	1M	N/A	1972
Dr. Eric J. Devroe Ph.D.	Chief Operating Officer	614.78k	N/A	1979
Ms. Katharine Peterson CPA	Vice President of Finance & Accounting	N/A	N/A	N/A
Dr. Adam D. Levy M.B.A., Ph.D.	Senior VP and Head of Investor Relations & Corporate Affairs	N/A	N/A	N/A
Mr. Bruce Close	Vice President of Quality & Compliance	N/A	N/A	N/A
Ms. Parvin Miah	VP & Head of Human Resources	N/A	N/A	N/A
Dr. Erick Gamelin M.D., Ph.D.	Chief Development Officer	480.72k	N/A	1958

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Corporate Governance

Acrivon Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.